Teva Pharmaceuticals Gets Exclusive Rights to OTC Emergency Contraception
The US Food and Drug Administration has given Teva Pharmaceuticals, the makers of brand name emergency contraception pill Plan B One-Step, exclusive rights to sell their product on store shelves without age restrictions for three years. Generic versions of pill will remain behind the counter and only be available to those 17 years of age or older.
Plan B One-Step costs approximately $50, whereas generic versions cost between $35 and $40. However, with the exclusive rights for Teva, the cost-effective versions will still be denied to young girls or those who do not have government issued identification, creating a barrier for many women and girls. Teva has promised to not increase the price of the drug while it has market exclusivity.
Janet Crepps, senior counsel at the Center for Reproductive Rights, told reporters "The FDA should have left open the option for all generic and potentially more affordable brands of emergency contraception to be made widely available, without delay."
The FDA cites clinical data Teva submitted in June that showed that Plan B One-Step could be safely taken by young teens as justification for exclusivity. Former FDA assistant commissioner for women's health, Susan Wood, told the Boston Globe, "The rationale behind exclusivity is that if a company does essential new research to get their product approved over-the-counter, they should get protection from generics for a little bit longer. But the data Teva was asked to collect wasn't actually essential, and now we're left in a confusing situation that makes it more expensive for women to get full access to emergency contraception."
In April, US District Judge Edward Korman ruled that the FDA must make single-pill versions of the morning-after pill available to women and girls of all ages and that it be made over the counter. Korman did not mandate that the restrictions be lifted from the two-pill versions. In June, the Obama Administration announced that it would not challenge the US Second Circuit Court's upholding of Korman's ruling.
Media Resources: Boston Globe 7/24/2013; ThinkProgress 7/23/2013; Feminist Newswire 6/11/2013, 6/5/2013, 4/5/2013
10/30/2014 Medication Abortion Access Threatened by Oklahoma Court Ruling - An Oklahoma state district court judge has refused to block a state law restricting medication abortion, clearing the way for the law to go into affect on November 1.
The Oklahoma Coalition for Reproductive Justice, together with a local abortion clinic in Tulsa, challenged HB 2684 in September, arguing that the law was an unconstitutional restriction on non-surgical abortion in the earliest weeks of pregnancy. . . .
10/30/2014 UPS Switches Pregnant Worker Policy Ahead of Supreme Court Case - The United Parcel Service (UPS) is changing its policy on light duty assignments for pregnant workers, even though the company will stand by its refusal to extend accommodations to a former employee in an upcoming Supreme Court case.
UPS announced on Monday in a memo to employees, and in a brief filed with the US Supreme Court, that the company will begin offering temporary, light-duty positions to pregnant workers on January 1, 2015. . . .
10/30/2014 North Dakota Medical Students Speak Out Against Measure 1 - Medical students at the University of North Dakota School of Medicine and Health Sciences are asking North Dakotans to vote no on Measure 1, a personhood measure on the state ballot this fall.
The students issued published a letter in the Grand Forks Herald stating that they opposed Measure 1 in part because they are against "the government's taking control of the personal health care decisions of its citizens." Nearly 60 UND School of Medicine students signed the letter, citing concerns over the "very broad and ambiguous language" used in the proposed amendment, which has no regard for serious and life-threatening medical situations such as ectopic pregnancies.
Measure 1 would change the North Dakota state constitution to create an "inalienable right to life" for humans "at any stage of development" - including the moment of fertilization and conception. . . .